Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capvaxive in Pneumococcal Vaccine-naïve Japanese Adults 65+
NCT05633992Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease, sponsored by Merck & Co.. Started Jan 2023; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05633992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633992.